Trial reportThe journal of allergy and clinical immunology. In practice
Hypereosinophilic Syndrome Subtype Predicts Responsiveness to Glucocorticoids.
Trial report in The journal of allergy and clinical immunology. In practice. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed.
- Long-Term Efficacy and Safety of Benralizumab Treatment for PDGFRA-Negative Hypereosinophilic Syndrome.The journal of allergy and clinical immunology. In practice · 2025Trial
- Trial
- Mechanisms of glucocorticoid resistance in hypereosinophilic syndromes.Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology · 2019Trial
- Benralizumab forThe New England journal of medicine · 2019Trial
- Long-Term Clinical Outcomes of High-Dose Mepolizumab Treatment for Hypereosinophilic Syndrome.The journal of allergy and clinical immunology. In practiceTrial
- Efficiency of combined systemic glucocorticoids and narrowband ultraviolet B phototherapy in lymphocytic-variant hypereosinophilic syndrome.JAAD case reports · 2026Article
- Circulating eosinophils in patients with hypereosinophilic syndrome have heterogeneous immunophenotypes.The journal of allergy and clinical immunology. Global · 2026Article
- Real-world outcomes after anti-IL-5/anti-IL-5Rα treatment for hypereosinophilic syndrome: Systematic literature review.The journal of allergy and clinical immunology. Global · 2026Article
- [Efficacy and survival outcomes of patients with lymphocytic variant hypereosinophilic syndrome].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2025Article
- Lymphocytic Variant Hypereosinophilic Syndrome: Case Series From a Tertiary Referral Center in Canada.EJHaem · 2025Article
- Article
- Steroid-sparing benefits of biologic use in hypereosinophilic syndrome and substantial disease burden across subtypes.Frontiers in allergy · 2025Article
- A case report of right-sided heart failure secondary to JAK2-mutation Loeffler endocarditis.ESC heart failure · 2024Article
- Review
- Biologics and Hypereosinophilic Syndromes: Knowledge Gaps and Controversies.The journal of allergy and clinical immunology. In practice · 2023Article
- HES and EGPA: Two Sides of the Same Coin.Mayo Clinic proceedings · 2023Review
- Hypereosinophilic syndrome presenting with gastrointestinal manifestations.BMJ case reports · 2023Article
- Eosinophilic airway diseases: basic science, clinical manifestations and future challenges.European clinical respiratory journal · 2022Review
- Lessons learned from targeting eosinophils in human disease.Seminars in immunopathology · 2021Review
- Hypereosinophilic syndrome with multiorgan involvement: an interdisciplinary work-up.BMJ case reports · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundGlucocorticoids (GCs) are considered first-line treatment for platelet-derived growth factor α (PDGFRA)-negative hypereosinophilic syndromes (HESs). Despite this, little is known about clinical predictors of GC responsiveness in HES.
objectiveKnowledge of clinical and laboratory predictors of GC response before initiation of GC could lead to more rational selection of subjects with HES for whom earlier institution of second-line and alternative therapies would be appropriate.
methodsResponse to GC, as defined by the reduction of the absolute eosinophil count to below 1000/mm
resultsA total of 164 subjects with PDGFRA-negative HES were categorized according to GC response. Of them, 39% of the subjects responded to low dose (≤10 mg) prednisone, 9% did not respond to GC, and the remainder (52%) had variable responses to GC. The HES subtype diagnosis was the best predictor of response to GC with myeloid forms and lymphocytic variants of HES being the least responsive to GC.
conclusionsIn a large cohort of well-characterized subjects with HES, the odds of response to GC was predicted by HES subtype. Using this model, clinicians may more readily proceed to second-line agents in subjects with confirmed lymphocytic or myeloid forms of HES.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.